Inhibrx Long Term Debt 2020-2022 | INBX

Inhibrx long term debt from 2020 to 2022. Long term debt can be defined as the sum of all long term debt fields.
Inhibrx Annual Long Term Debt
(Millions of US $)
2021 $76
2020 $36
2019 $37
Inhibrx Quarterly Long Term Debt
(Millions of US $)
2022-03-31 $114
2021-12-31 $76
2021-09-30 $76
2021-06-30 $76
2021-03-31 $36
2020-12-31 $36
2020-09-30 $17
2020-06-30
2020-03-31
2019-12-31
2019-09-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.533B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00